Vanguard Growth ETF

Latest Vanguard Growth ETF News and Updates

  • uploads///eps estimates
    Earnings Report

    Will Medtronic Meet Analysts’ Earnings Estimates in Fiscal 1Q18?

    For the last several quarters, Medtronic has consistently exceeded analysts’ earnings estimates.

    By Sarah Collins
  • uploads///Humira Revenues
    Company & Industry Overviews

    Humira May Continue to Drive AbbVie’s Revenue Growth

    In 2016, AbbVie’s (ABBV) drug Humira reported revenue of ~$16.0 billion, which reflected a ~15% year-over-year (or YoY) rise.

    By Daniel Collins
  • uploads///
    Consumer

    Michael Kors Beats 1Q18 Expectations, Raises Guidance

    For fiscal 1Q18, Kors’s EPS came in at $0.90, or $0.28 higher than the estimate. Its revenue fell 3.6% YoY to $952 million but still beat the consensus estimate.

    By Sonya Bells
  • uploads///Interferon revenues
    Company & Industry Overviews

    Biogen’s Interferon Therapies Could Witness Modest Fall in 2017

    In 2016, Biogen’s (BIIB) interferon therapies, Avonex and Plegridy, together reported revenues of around $2.8 billion, which reflected a drop of ~6% on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Part
    Earnings Report

    Wall Street Expects 16.5% Earnings Growth from UA in 4Q15

    Under Armour (UA) has an enviable earnings record. It’s beaten the market consensus on quarterly earnings and sales for over five years in a row.

    By Phalguni Soni
  • uploads///
    Consumer

    1Q18: Will Michael Kors Post another Weak Quarter?

    Michael Kors Holdings Limited (KORS) is slated to report its 1Q18) earnings results on Tuesday, August 8. Here’s what you need to know.

    By Sonya Bells
  • uploads///PD  class action
    Company & Industry Overviews

    Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class

    The PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1) class consists of Bristol-Myers Squibb’s Opdivo, Merck’s Keytruda, and Roche’s Tecentriq.

    By Jillian Dabney
  • uploads///Part
    Company & Industry Overviews

    Fleet of Foot? Foot Locker’s Fastest-Growing Sales Segments

    In fiscal 2016, Foot Locker made $5.3 billion in US sales, representing 71.6% of its total revenue. In contrast, international revenue came in at $2.1 billion.

    By Phalguni Soni
  • uploads///Graph
    Company & Industry Overviews

    AbbVie’s Rova-T: Solid Growth Driver for the Future?

    AbbVie (ABBV) aims to position its investigational therapy Rova-T (rovalpituzumab tesirine) as a standard of care treatment for patients with SCLC (small cell lung cancer).

    By Margaret Patrick
  • uploads///GROWTH INDEX EXPO TO IT
    Consumer

    Total Returns and Sector Exposure for Growth Indexes

    If we dig into the S&P 500 and the S&P Growth indexes, we can see that they have the highest exposure to information technology (or IT).

    By Amanda Lawrence
  • uploads///Interferons
    Company & Industry Overviews

    How Biogen’s Biosimilars and Interferons Performed in 4Q17

    In 4Q17, Biogen’s (BIIB) interferons generated revenues of $645 million, which reflected a 6% decline YoY and a 3% decline on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///recommendations
    Earnings Report

    Analyst Ratings for Thermo Fisher Scientific before 4Q17 Results

    Thermo Fisher Scientific (TMO) will announce its 4Q17 and fiscal 2017 results on January 31, 2018. It has launched some innovative products and entered into strategic collaborations and partnerships.

    By Sarah Collins
  • uploads///value chain
    Company & Industry Overviews

    Align Technology’s Customer Acquisition Strategy Driving Market Growth

    In 3Q17, Align Technology trained nearly 1,000 doctors in China.

    By Sarah Collins
  • uploads///free cash flow
    Company & Industry Overviews

    What’s Driving Baxter International’s Cash Flow Growth

    Baxter International’s 2017 cash flow Between 9M16 (the first nine months of 2016) and 9M17, Baxter International’s (BAX) cash flow rose by $514 million to $933 million, exceeding its cash flow of $905 million in fiscal 2016. In fiscal 9M17, Baxter had operating cash flow of ~$1.3 billion, up $405 million from fiscal 9M16. In fiscal 2017, Baxter expects to […]

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    AbbVie’s Position in the Growing Oncology Market in 2018

    AbbVie (ABBV) is focused on advancing its already strong position in the hematologic oncology segment in 2018.

    By Margaret Patrick
  • uploads/// Smart beta
    Real Insights

    Can Smart Beta Go Wrong?

    The smart beta approach aims to benefit from market inefficiencies to deliver higher risk-adjusted returns and improve diversification.

    By VanEck
  • uploads///stock price
    Company & Industry Overviews

    Why Boston Scientific Stock Fell 9% in Two Days

    Boston Scientific (BSX) stock fell ~7.5% on November 28, 2017, triggered by the speculation of bad news.

    By Sarah Collins
  • uploads///Chart  AGN
    Healthcare

    Allergan Stock: Performance in 3Q17

    Allergan stock has fallen ~15.4% in 3Q17. It has fallen 9.8% year-to-date as of October 20, 2017.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What’s Medtronic’s Long-Term Growth Strategy for Its Diabetes Business?

    Medtronic (MDT) expects its diabetes business to witness a temporary sequential drop in revenues in 2Q18 and then return back to growth in the second half of fiscal 2018.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Could Mylan’s Biosimilar Portfolio Be a Long-Term Growth Driver?

    According to a Deloitte report, the biosimilars market is expected to grow to a market value of more than $445.0 billion by the end of 2019.

    By Margaret Patrick
  • uploads///margin
    Company & Industry Overviews

    Boston Scientific’s Updated 2017 Guidance

    Boston Scientific (BSX) expects to register 2017 revenues of $8.9 billion–$9.0 billion compared to its previous guidance of $8.8 billion–$8.9 billion.

    By Sarah Collins
  • uploads///Orkambi Kalydeco
    Company & Industry Overviews

    How Are Orkambi and Kalydeco Positioned after 2Q17?

    In 2Q17, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $324 million, which reflected a whopping ~32% growth on a year-over-year (or YoY) basis and ~10% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///results
    Company & Industry Overviews

    Did June’s IT Disruption Hurt Medtronic’s Sales in Fiscal 1Q18?

    On June 19, 2017, Medtronic (MDT) experienced a global technology glitch, which led to IT disruption throughout the company.

    By Sarah Collins
  • uploads///Dupixent
    Company & Industry Overviews

    Dupixent and Kevzara: Regeneron’s Long-Term Growth Drivers?

    In 2Q17, Regeneron Pharmaceuticals’ (REGN) Dupixent generated revenues of $28.6 million.

    By Daniel Collins
  • uploads///dispensing business model change
    Company & Industry Overviews

    Headwind for Becton Dickinson: US Dispensing Business

    Becton Dickinson (BDX) is the leading player in the US dispensing business. Its Pyxis system sales contribute significantly to the company’s total revenues.

    By Sarah Collins
  • uploads///PROTON THERAPY
    Company & Industry Overviews

    How Varian Is Harnessing Proton Therapy Market Opportunities

    Proton therapy market opportunities The proton therapy market is a highly lucrative opportunity area for Varian Medical Systems (VAR). Proton therapy uses protons for treating cancer instead of X-rays. According to a Medgadget report, the global proton therapy market is expected to double by the year 2022. Though the United States has the biggest proton […]

    By Sarah Collins
  • uploads///Otezla
    Company & Industry Overviews

    Celgene’s Otezla Witnessed High Revenue Growth in 2Q17

    In 2Q17, Celgene’s (CELG) Otezla generated revenues of around $358 million, which reflected ~49% growth on a year-over-year basis.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Edwards Lifesciences Focuses on Indication Expansion of SAPIEN 3 in 2017

    To further expand the label of its transcatheter heart valve (or THV), SAPIEN 3, Edwards Lifesciences (EW) is currently involved in enrolling patients in its EARLY-TAVR trial.

    By Margaret Patrick
  • uploads///Orencia revenues
    Company & Industry Overviews

    Why Orencia Could Be Just What BMY Needs in 2017

    In 2016, Bristol-Myer Squibb’s (BMY) Orencia reported revenues of around $2.3 billion, which represents a ~20% YoY rise.

    By Daniel Collins
  • uploads///pipeline
    Company & Industry Overviews

    Inside Vertex Pharmaceuticals’ Clinical Pipeline

    In March 2017, Vertex Pharmaceuticals (VRTX) announced promising results from two phase-3 clinical trials, Evolve and Expand.

    By Daniel Collins
  • uploads///Otezla revenues
    Company & Industry Overviews

    Otezla Could Significantly Drive Celgene’s Revenue Growth

    In 2016, Celgene’s (CELG) Otezla generated revenues of around $1.0 billion, a 116% year-over-year (or YoY) increase.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Dupixent May Be a Major Growth Driver for Regeneron in 2017

    After Dupixent’s commercial launch, Regeneron has been involved in creating awareness for the drug among physicians who have been treating AD patients.

    By Margaret Patrick
  • uploads///geographic segmentationn
    Company & Industry Overviews

    How Stryker Plans to Capture the International Markets

    Most of Stryker’s emerging market sales are from China. However, Europe and emerging markets sales have witnessed high growth in recent quarters.

    By Sarah Collins
  • uploads///Kyprolis Clinical Trial Result
    Company & Industry Overviews

    Kyprolis Could Significantly Drive Amgen’s Revenue Growth in 2017

    Amgen’s (AMGN) Kyprolis has gained considerable market share in second-line multiple myeloma (or MM) indication since its launch in 2012.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    ALXN1210 Is Expected to Boost Alexion Pharmaceuticals’ Revenue

    Alexion Pharmaceuticals has planned five clinical trials in 2017 to test the potential of investigational next-generation C5 antibody, ALXN1210, as a treatment option for complement-mediated diseases.

    By Margaret Patrick
  • uploads///core strategies
    Earnings Report

    What Are Stryker’s Key Growth Drivers for 2Q17?

    Stryker has registered strong revenues and earnings in the last few quarters.

    By Sarah Collins
  • uploads///be medical
    Company & Industry Overviews

    BD’s Medical Segment Performance and Growth Strategy

    The BD Medical business generated revenues of ~$8.7 billion in fiscal 2016, which ended September 30, 2016.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Acute Myeloid Leukemia: Growth Opportuny for AbbVie’s Venclexta?

    AbbVie’s (ABBV) Venclexta has been granted FDA breakthrough therapy designation as a first line therapy for patients with acute myeloid leukemia who are ineligible for high-dose chemotherapy.

    By Margaret Patrick
  • uploads///operating segments
    Earnings Report

    How Did Mallinckrodt’s Specialty Brands Perform in 2016?

    Specialty Brands had a 69% in Mallinckrodt’s total revenue in 2016, while Specialty Generics had a 31% share.

    By Jillian Dabney
  • uploads///Change in the Federal Funds Rate
    Macroeconomic Analysis

    How the Next President Could Shape US Monetary Policy

    The Federal Reserve’s second last meeting of 2016 is now over, leaving only one meeting left in which the central bank can enact a rate hike.

    By David Ashworth
  • uploads///Profit GDP
    Company & Industry Overviews

    What’s Fueling the Bull Run? Richard Bernstein Explains

    A bull run with legs In Richard Bernstein Advisors’ October Insights newsletter, after dismissing the belief that the Federal Reserve is to blame for stock price inflation (IWD) (VTV), Richard Bernstein moved on to explain the reason for the current bull run. Stating that “fundamentals have improved dramatically, and have been a major support to the […]

    By David Ashworth
  • uploads///Yield Movement Before and During Taper Tantrum
    Macroeconomic Analysis

    Why Were Fed Policymakers Worried about Clear Communication?

    The credibility of the Federal Reserve was a concern raised by some policymakers at the September FOMC (Federal Open Market Committee) meeting.

    By David Ashworth
  • uploads///dupilumab
    Earnings Report

    Regeneron’s Dupilumab: How Much Potential Does It Hold?

    Dupilumab has a breakthrough therapy designation from the FDA for the indication of moderate-to-severe atopic dermatitis in adults.

    By Jillian Dabney
  • uploads///market share
    Company & Industry Overviews

    How Is Varian Positioned in the Particle Therapy Business?

    Varian Medical Systems (VAR) had gross orders value of $310 million in 2015.

    By Sarah Collins
  • uploads///daccdecffcefbcceadfcd
    Company & Industry Overviews

    Why Is the PE Ratio Important to a Bull Market?

    An assessment of a bull market isn’t complete without looking at the companies’ PE ratios. Generally, the ratio rises during a bull market.

    By David Ashworth
  • uploads///combined business profile
    Company & Industry Overviews

    Introducing Dentsply Sirona, a Leading Dental Products Manufacturer

    Dentsply Sirona (XRAY) is the largest manufacturer of dental equipment and technologies in the world. The company was formed in February 2016.

    By Sarah Collins
  • uploads///installed base
    Company & Industry Overviews

    Exploring Intuitive Surgical’s Sales Model

    Intuitive Surgical follows a diversified sales strategy and doesn’t generate more than 10% of its revenue through any one customer.

    By Sarah Collins
  • uploads///xtandi duration
    Earnings Report

    Could Medivation’s Xtandi Become a Major Urology Drug?

    Although Medivation’s (MDVN) Xtandi is a leader in the oncology space, it has significant opportunity in the urology space as well.

    By Jillian Dabney
  • uploads///segment revenues
    Earnings Report

    How Did Edwards Lifesciences’ Critical Care Segment Fare in 1Q16?

    Edwards Lifesciences (EW) reported ~$697 million in total revenue in 1Q16. Of that, ~$134 million was contributed by the company’s Critical Care segment.

    By Sarah Collins
  • uploads///VOD
    Company & Industry Overviews

    Defitelio: Volume and Pricing Challenges

    Jazz Pharmaceuticals’ Defitelio is the first and only approved treatment that increases survival in VOD patients with multi-organ dysfunction (or MOD).

    By Jillian Dabney
  • uploads///Revs distri for DIS in Q
    Macroeconomic Analysis

    Affiliate Fees and Content Licensing Revenues for the Media Sector

    Media companies primarily derive their revenues mainly from affiliate fees and advertising. Affiliate fees are the carriage fees paid per month per subscriber by multichannel video programming distributors like Comcast and Dish Network.

    By Shirley Pelts
  • uploads///oil and gas companies that filed for bankruptcy in
    Miscellaneous

    Why Minimum Volume Commitments May Not Protect MLPs

    While minimum volume commitments work well, in general, things change in a sustained low commodity price environment. Currently, this is the case.

    By Rekha Khandelwal, CFA
  • uploads///ESPN subs
    Company & Industry Overviews

    Are Skinny Bundles the Way Forward for the Media Sector?

    Pay-TV operators like Dish are offering a skinny bundle of channels to woo these Millennials back to pay-TV. However, media companies have been reluctant to license their channels to skinny bundles.

    By Shirley Pelts
  • uploads///ANR
    Earnings Report

    Regeneron Pharmaceuticals’ Research Pipeline and Analyst Recommendations

    The consensus revised 12-month target price for Regeneron is now $523.8, suggesting a ~42.6% return compared to its closing price of $367.2 on February 9.

    By Jillian Dabney
  • uploads///Graph
    Earnings Report

    AbbVie’s Late-Stage Research Pipeline Could Boost Future Revenues

    In partnership with Bristol-Myers Squibb, AbbVie is exploring elotuzumab to treat relapsed refractory multiple myeloma. The drug also received a breakthrough therapy designation from the FDA on May 19, 2014.

    By Margaret Patrick
  • uploads///Series A
    Miscellaneous

    Nvidia Loses Patent Lawsuit against SSNLF, QCOM

    Nvidia has been found guilty by the US International Trade Commission judge for infringing on two of three patents in question.

    By Puja Tayal
  • uploads///Graph
    Earnings Report

    How Does Gilead Sciences Return Capital to Shareholders?

    In 3Q15, Gilead Sciences returned capital to shareholders through share repurchase programs, cash dividend programs, and warrants repurchases.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Gilead Sciences Continued to Expand HCV Markets in 3Q15

    3Q15 sales of the company’s HCV products, distributed across the US, Europe, and international markets, amounted to $3.2 billion, $869 million, and $696 million, respectively.

    By Margaret Patrick
  • uploads///Part
    Company & Industry Overviews

    Future Sales Drivers for Nike’s Integrated Marketplace Model

    Nike is expecting sales through wholesalers to grow at a mid- to high-single compounded annual growth rate over the next five years through fiscal 2020.

    By Phalguni Soni
  • uploads///Time spent on TV and ad spend on TV april
    Macroeconomic Analysis

    Advertising Revenues Decline, Affecting Media Companies

    The advertising market is seeing a shift from TV to digital. The average time spent per day by US adults watching TV is steadily declining and is expected to be 36.4% of their media time in 2015.

    By Shirley Pelts
  • uploads///Part
    Company & Industry Overviews

    Discovering VF Corp.’s Marketing Edge

    VFC’s marketing dollars are designed to get the most returns from its stores, other retailers (wholesale customers), and its e-commerce websites.

    By Phalguni Soni
  • uploads///Part
    Company & Industry Overviews

    Which Way Is The Wind Blowing For Lululemon’s Cost Trends?

    Cost-side factors are also expected to affect profitability in fiscal 2015, with gross margin falling between 51% and 52%, down from 53.9% in fiscal 2014.

    By Phalguni Soni
  • Consumer

    Must-know: NASDAQ ETFs offer better returns than growth stocks!

    The technology sector has seen healthy growth over the past five years, generating good returns for its investors. This trend has reflected in the performance of NASDAQ-listed tech-heavy exchange-traded funds like the PowerShares QQQ Trust, Series 1 ETF (QQQ).

    By Surbhi Jain
  • Technology & Communications

    Why is the NASDAQ heavily weighted towards technology stocks?

    The NASDAQ’s upstart image and all-electronic trading platform have attracted more technology-based companies. Many of these companies didn’t qualify to list on the NYSE when they originally went public.

    By Surbhi Jain
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.